Fact Sheets
Treatment Options for Latent Tuberculosis
Infection
Last Updated: April 2005
Introduction
Treatment of latent tuberculosis infection (LTBI) substantially
reduces the risk that infection will progress to disease. Once the
diagnosis of LTBI has been made, health care providers must choose
the most appropriate and effective treatment regimen.
Pretreatment Evaluation
To decide whether an individual who has a positive tuberculin
skin test (TST) or blood test (QuantiFERON®-TB Gold) result
is a candidate for treatment of LTBI
- Determine the benefits of treatment by evaluating individual's
risk for developing TB disease
- Assess the person's level of commitment to completion of treatment
and resources available to ensure adherence
Once the decision is made to treat an individual for LTBI, the
health care provider must establish rapport with the patient and
- Discuss risks and benefits of treatment
- Review possible medication side effects or drug interactions
- Emphasize importance of adherence
- Identify potential barriers to adherence
- Establish a plan to ensure adherence
Choosing the Most Effective Regimen
Treatment of LTBI should be initiated after the possibility of
TB disease has been excluded. The three treatment regimens use isoniazid
(INH) or rifampin (RIF) (see Table 1). INH for 9 months is the
preferred regimen. Treatment must be modified if the patient
is a contact of an individual with INH or multidrug-resistant TB.
Consultation with a TB expert is advised when the index patient
has multidrug resistant TB.
Table 1. LTBI Treatment Regimens
Drugs/Regimen |
Interval |
Minimum # of doses for treatment completion |
Rating for HIV-negative persons |
Rating for HIV-positive persons |
Isoniazid/
9 month |
Daily |
270 |
A (II) |
A (II) |
Twice weekly |
76 |
B (II) |
B (II) |
Isoniazid/
6 month |
Daily |
180 |
B (I) |
C (I) |
Twice weekly |
52 |
B (II) |
C (II) |
Rifampin/4 month |
Daily |
120 |
B (II) |
B (III) |
Rifampin and Pyrazinamide/
2 months |
Due to the reports of severe liver injury and
deaths, the combination of rifampin and pyrazinamide should
generally not be offered for the treatment of LTBI. |
D (II) |
D (II) |
Using the U.S. Public Health Service system, CDC and ATS have ranked
these regimens according to the strength of the recommendation and
the quality of supporting evidence
* Strength of recommendation: A = preferred; B = acceptable alternative;
C = offer when A and B cannot be given; D = should generally not
be offered
† Quality of supporting evidence: I = randomized clinical
trial data; II = data from clinical trials that are not randomized
or were conducted in other populations; III = expert opinion
Monitoring During Treatment
Baseline and routine laboratory monitoring during treatment of
LTBI are indicated only when there is a history of liver disease,
HIV infection, pregnancy (or within 3 months post delivery), or
regular alcohol use. Baseline hepatic measurements of serum AST,
ALT, and bilirubin are used in the situations mentioned above and
to evaluate symptoms of hepatotoxicity.
Clinical monitoring, including a brief physical examination, should
occur at monthly visits to assess adherence and identify signs or
symptoms of adverse drug reactions.
Drug-Drug Interactions
Obtain a list of patient’s current medications to avoid
drug interactions. Some interactions to note:
- INH increases blood levels of phenytoin (Dilantin) and disulfiram
(Antabuse)
- Rifampin decreases blood levels of many drugs including oral
contraceptives, warfarin, sulfonureas, and methadone
- Rifampin is contraindicated in HIV-infected individuals being
treated with protease inhibitors (PIs) and most nonnucleoside
reverse transcriptase inhibitors (NNRTIs)
Side Effects
Patients on treatment for LTBI should be instructed to report any
potential medication side effects to their health care provider,
including
- Unexplained anorexia, nausea or vomiting, dark urine*, or icterus
- Persistent paresthesia of hands or feet
- Persistent weakness, fatigue, fever, or abdominal tenderness
- Easy bruising or bleeding
*Advise patients taking RIF that they will notice a normal orange
discoloration of body fluids. Contact lenses may be permanently
stained.
References
ATS/CDC.
Targeted tuberculin testing and treatment of latent tuberculosis
infection. MMWR 2000;49 (No. RR- 6).
ATS/CDC.
Update: Adverse Event Data and Revised American Thoracic Society/CDC
Recommendations Against the Use of Rifampin and Pyrazinamide for
Treatment of Latent Tuberculosis Infection. MMWR 2003;
52 (No. 31).
ATS/CDC.
Treatment of tuberculosis. MMWR 2003;52 (No. RR-11).
Updated
Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis
Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside
Reverse Transcriptase Inhibitors. MMWR 2004: 53 (No.
2)
Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis
Additional Resources
Website:
TB Education and Training Resources website
The following resources can be viewed and downloaded from the CDC
TB website.
Slide Set:
Fact Sheets:
Last Reviewed: 05/18/2008 Content Source: Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
|